PO Administer once daily without regard to food. Swallow capsule whole; do not open, crush, or chew.
Instruct patient to take as directed. If a dose is missed, skip missed dose. Do not make up dose. Resume dosing with next scheduled dose.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Discuss the possibility of hair loss with patient. Explore methods of coping.
Advise patient not to donate blood during therapy and for at least 24 mo after last dose.
Rep: Vismodegib can cause fetal harm. Advise male and female patient to use a highly effective method (IUD, hormonal contraceptive, tubal ligation, partner's vasectomy) of contraception during and for at least 24 mo after therapy for women. Male patients receiving vismodegib must always use condoms with spermicide during any contact with females with child-bearing potential, even if they have undergone a successful vasectomy, and may not donate sperm during and for at least 3 mo after completion of therapy. Instruct patient to notify health care professional promptly if pregnancy is suspected or if breastfeeding. Advise women to avoid breastfeeding during and for 24 mo after final dose of vismodegib. May cause amenorrhea with unknown reversibility. Encourage women who have been exposed to vismodegib either directly or through seminal fluid, to participate in ERIVEDGE pregnancy pharmacovigilance program by contacting the Genentech Adverse Event Line at 1-888-835-2555.
Decreased spread of basal cell carcinoma.
vismodegib is a sample topic from the Davis's Drug Guide.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Complete Product Information.